HeberFERON® as a therapeutic option in basal cell carcinoma. Case report

Authors

Abstract

Introduction: skin cancer is the main cause of malignant tumors in the world. This information is relevant in the elderly, as part of all the changes experienced during aging. In Cuba, studies indicate that this type of carcinoma represents 75-80 % of diagnosed skin neoplasms, which places it within the Latin American countries with the highest incidence of non-melanotic skin cancer.

Objective: to present a patient with basal cell carcinoma located in the lower eyelid of the left eye, with possible compromise of the ocular anatomy if he underwent surgery, and for this reason he was successfully treated with HeberFERON®.

Case presentation: a 78-year-old white male patient with a history of diabetes mellitus and a history of chronic sun exposure. He came to the clinic for presenting three localized skin lesions, months of evolution, rapid growth, and easy bleeding. During the anamnesis, he stated that he had worked for many years in construction, without using sun protection. Skin biopsy of the larger lesion resulted in an ulcerated solid basal cell carcinoma, and treatment with HeberFERON® was indicated for this lesion, and excision for the minors, once its size decreased.

Conclusions: treatment with HeberFERON® constitutes a therapeutic option to avoid surgical interventions that compromise the facial anatomy. Its use is recommended in patients with basal carcinoma in locations similar to those of the patient in this study

Downloads

Download data is not yet available.

Published

2021-10-25

How to Cite

1.
del Río Ysla MB, Abreu Rivero Y, Valle Yanes I. HeberFERON® as a therapeutic option in basal cell carcinoma. Case report. Mediciego [Internet]. 2021 Oct. 25 [cited 2024 Dec. 21];27(1):e2057. Available from: https://revmediciego.sld.cu/index.php/mediciego/article/view/2057

Issue

Section

Case Report

Most read articles by the same author(s)

1 2 > >>